WJA
BPMC

Williams Jones & Associates’s Blueprint Medicines BPMC Stock Holding History

Williams Jones & Associates’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-13,150
Closed -$346K – 366
2015
Q4 		$346K Sell
13,150
-10,250
-44% -$231K 0.02% 252
2015
Q3 		$499K Sell
23,400
-7,700
-25% -$213K 0.02% 232
2015
Q2 		$824K Buy
+31,100
New +$888K 0.03% 208

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Williams Jones & Associates's BPMC Position: Q1 2016 in Review

Williams Jones & Associates sold out of Blueprint Medicines (BPMC) in Q1 2016, closing a stake of 13,150 shares — an estimated $346K sold.

Williams Jones & Associates first reported a position in BPMC in Q2 2015 and held it in 3 quarters. The position peaked at $824K in Q2 2015. 70 funds tracked by Wall St. Rank hold BPMC as of Q1 2016.

  • Williams Jones & Associates reported no remaining Blueprint Medicines position as of Q1 2016 after selling out during the quarter.
  • Williams Jones & Associates sold 13,150 Blueprint Medicines shares in Q1 2016, an estimated $346K.
  • Williams Jones & Associates first reported a position in Blueprint Medicines in Q2 2015 and held it in 3 quarters.
  • Williams Jones & Associates's Blueprint Medicines position peaked at $824K in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2016.

Based on Williams Jones & Associates's 13F filing for Q1 2016, filed 16 May 2016.